Please login to the form below

Not currently logged in
Email:
Password:

Amarin

This page shows the latest Amarin news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

Amarin was hit again in September 2020, after the US Court of Appeals upheld the lower court’s ruling that invalidated the patents covering Vascepa. ... In a statement, Amarin said that it would be ‘reviewing its legal options’ following the US

Latest news

  • Amarin shares tumble following Vascepa patent loss Amarin shares tumble following Vascepa patent loss

    is approved by FDA, prevent launch of generic versions of Vascepa,” said John Thero, CEO of Amarin. ... The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.

  • Northsea Therapeutics raises $40m to develop fish oil NASH drug Northsea Therapeutics raises $40m to develop fish oil NASH drug

    The outlook for Northsea looks positive given Amarin’s success with its own fish oil-derived drug Vascepa (icosapent ethyl). ... This blockbuster indication has Amarin “aggressively launching” Vascepa in the US, after the company estimated expected

  • FDA okays Amarin’s Vascepa for cardiovascular risk reduction FDA okays Amarin’s Vascepa for cardiovascular risk reduction

    Drug is on course for blockbuster sales. Amarin has been given an early Christmas present by the FDA – the approval of its fish oil-derived drug Vascepa to reduce the risk ... The expanded approval for Amarin’s only marketed product was odds on after

  • Amarin files fish oil-based heart drug Vascepa in Europe Amarin files fish oil-based heart drug Vascepa in Europe

    The European Medicines Agency (EMA) has started a review of Irish drugmaker Amarin’s fish oil-derived drug – sold as Vascepa in the US – setting up an approval next year. ... as Amarin starts to expand its salesforce for the drug from 400 to 800

  • Amarin wins FDA advisory nod for Vascepa cardiovascular expansion Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

    We appreciate both the opportunity to present these results and the committee’s strong vote of confidence,” said John Thero, president and chief executive officer of Amarin. ... These gains also lend more credit to the ongoing  speculation that

More from news
Approximately 11 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Teva's Mark Salyer joins Amarin Teva's Mark Salyer joins Amarin

    Takes up newly-created chief commercial officer role. Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer. ... Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...